BioArctic AB (BRCTF) announced Wednesday that Australia's Therapeutic Goods Administration (TGA) has approved Leqembi for the treatment of adults with early Alzheimer's disease.
BioArctic holds the rights to commercialize Leqembi, developed in collaboration with Eisai Co Ltd (ESALY.PK), in the Nordic region, and the two companies are preparing for a joint commercialization in the region.
The approval comes after the TGA initially declined Leqembi in February 2025. Eisai requested a review in March, and subsequent discussions with the TGA led to an agreement that secured Leqembi's approval.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.